R&D

Technology

NCE Discovery

Poziotinib (pan-HER)
  • Irreversible potent pan-HER inhibitor
  • Effective and tolerable for Her-2 & EGFR driven cancers
Olita®(olmutinib)
  • Selective & excellent activity to EGFR mutants including T790M
  • Clinical trial being conducted in advanced NSCLC patients with EGFR mutations
  • May 2016. Accelerated approval granted by MFDS (Korean Brand name: Olita® Tab.)
HM71224 (BTK)
  • Irreversibly designed Bruton's tyrosine kinase (BTK) inhibitor
  • Potent inhibition of BTK signaling in B cell such as p-BTK and p-PLCγ
HM95573 (RAF)
  • Selective pan-RAF inhibitor
  • Potentially targeting B-RAFmut and/or N-RASmut /C-RAF driven cancers